Biotinidase deficiency: What have we learned in forty years?

Details

Ressource 1Download: 1-s2.0-S1096719223001907-main.pdf (451.49 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_794C2E8293EE
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Biotinidase deficiency: What have we learned in forty years?
Journal
Molecular genetics and metabolism
Author(s)
Tankeu A.T., Van Winckel G., Elmers J., Jaccard E., Superti-Furga A., Wolf B., Tran C.
ISSN
1096-7206 (Electronic)
ISSN-L
1096-7192
Publication state
Published
Issued date
04/2023
Peer-reviewed
Oui
Volume
138
Number
4
Pages
107560
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Biotinidase deficiency (BD) is an autosomal recessively inherited disorder that was first described in 1982. Forty years after its first description, we compiled available clinical data on BD with the aim of generating a more comprehensive picture of this condition.
A systematic search strategy was performed in relevant databases without limits for publication date or languages. We screened 3966 records and included 144 articles reporting individuals with BD and their clinical presentation as well as the outcomes, when available.
This study included 1113 individuals with BD. More than half (51.5%) of these individuals were diagnosed by newborn screening, 43.3% in presence of clinical symptoms and 5.2% due to family screening. We grouped symptomatic individuals into four main clinical presentations: neonatal-onset (<1 month; 7.9%), early childhood-onset (<2 years; 59.2%), juvenile-onset (2-16 years; 25.1%) and adult-onset (>16 years; 7.7%). BD affected five main organ systems: nervous system (67.2%), skin (53.7%), eye (34.4%), auditory (26.9%) and respiratory system (17.8%). Involvement was mainly multisystemic (82.2%) of individuals, whereas isolated system presentation was seen in only 17.2% of individuals. When reported, metabolic acidosis was present in 42.4% of symptomatic individuals and characteristic abnormal organic acid metabolites were found in 57.1%. Biotin treatment led to clinical stability or improvement in 89.2% of individuals. 1.6% of reported individuals with BD died due to non-availability of treatment or late diagnosis.
Newborn screening has had a major positive impact on the outcome of many individuals with BD. However, undiagnosed and non-treated BD remains a health concern. Given the risk of mortality or complications associated with late or missed diagnosis if newborn screening is not available, a trial of biotin should be considered in undiagnosed infants and adults exhibiting suspected clinical signs. Enzymatic activity and/or analysis of genetic variants can readily confirm the diagnosis of BD.
Keywords
Infant, Infant, Newborn, Adult, Child, Preschool, Humans, Biotinidase Deficiency/diagnosis, Biotinidase Deficiency/genetics, Biotin/therapeutic use, Biotinidase/genetics, Biotinidase/metabolism, Neonatal Screening, Databases, Factual, Biotin, Biotinidase, Biotinidase deficiency, Newborn screening, Outcomes
Pubmed
Web of science
Open Access
Yes
Create date
17/04/2023 11:01
Last modification date
15/06/2023 7:12
Usage data